There is a perception that 'Big Pharma' is strictly out for profit and that pharmaceutical companies will stop at nothing to line the pockets of their shareholders. The reality is this: Many of these drugs are saving lives and helping people live happier, healthier lives.
Sintetica established in 1921, is a pharmaceutical company which delivers injectable anaesthetics and analgesics to patients across the globe via innovative science and excellence in development, production and marketing. The company employees 300 people from 29 different countries across the globe.
It is headquartered in Mendrisio, Switzerland and its sites are located in Switzerland, Germany, Austria, Italy and United Kingdom.
The Swiss manufacturing sites of Mendrisio and Couvet have production capacity of 60 million ampoules, 5 million infusion bags and over 5 million vials (production capacity increase to 10 million on going).
Local anesthesia and pain relief are the two areas in which Sintetica has been the market leader for many years in Switzerland. Moreover, it is also seeking to develop a leadership position in the growing field of neuromodulation.
At the beginning of 2012, the company established a global division which was the first international corporate structure. The global division was tasked with pursuing international growth under two distinct models, being a B2B licensing strategy and somewhat later a B2C strategy in select markets.
Under the B2B model, the company sought to license out its top brands to partners with whom it shared values. Foremost among these values is that people and relationships, including business relationships, come first, and thus Sintetica seeks to build business by finding partners with whom it can share its values. As such, all the company’s partners must meet strict ethical criteria and share its innovation driven ‘quality without compromise’ value proposition. This was the most critical and difficult challenge it has faced since beginning of its internationalization efforts; however Augusto, CEO is proud to say that the company has been very successful.
When asked about the company’s current scenario, Sintetica team said they have submitted more than 350 product registrations in over 100 different countries via the network of partners it has built over the last five years. The first phase of expansion covered North, Central and South America, South East Asia, and the Pacific. Many of these registrations have yet to come through, but so far the company has seen strong growth in the US, and some good returns in the Pacific. YOY Global Division growth is exceeding 200%, consolidating the impressive growth stream of the last years.
Sintetica is fully committed to innovative therapies and drugs in local anesthesia, pain management and neuromodulation. As such, the firm moves forward with passion and competence in the full respect of people and the environment. All its efforts and resources are focused to become leader in these fields by developing novel medicine and better treatment options for physicians and patients worldwide.
“To achieve this leadership by innovation in the context of global growth, we consider strategic partnering and business development the key factors”.
Global division is therefore focusing on high speed robust partner selection and affiliation in every country of the world. It is determined to offer a dynamic portfolio of selected branded medicines, developed to answer unmet clinical needs, to build sustainable and long lasting alliances.
When discussed about what makes Sintetica unique from competitors, Augusto replied, “Respect is the core value of the company and it permeates across every employee. The concept of respect is divided into three well-defined directions. It is expressed in relation to its employees, enhancing the different characteristics of each one. Whether for work or as an individual, through activities which create a pleasant environment in which to work and express themselves.”
This same concept is also expressed towards the patients using Sintetica drugs worldwide, providing them with the highest quality products and investing in innovation to imagine the best care solutions for the future. Consequently, it materializes towards its global partners, showing them loyalty, absolute ethics and both operational and development support of advanced market strategies.
The convergence of these three well-defined areas makes up the Sintetica Value Proposition. It is a distinct and strategic element in the wide world panorama of the pharmaceutical industry.
Sintetica seriously takes the obligation to meet the highest standards of business ethics and integrity, and make meeting those standards the responsibility of all its employees. That is why, when hiring new employees, the company looks for ‘smart’ people who share its thirst for diversity, its respect for traditions and its aim to be a global leading company.
Augusto believes in a company culture that promotes creativity and informed risk taking. In this respect, it must also promote a good feeling for all employees that work here, who should always feel safe when they are in work.
Making Sintetica a great place to work is Augusto’s firm belief, something that is very much a part of the company DNA. He considers his people to be the company’s core resource. That is why he can trust those who work in the organization to open to change and drive the innovation in management process in the long-term.
What does the future hold for SINTETICA?
Augusto replies: Hopefully a lot of good news and strong returns to my team’s great efforts!
We recently obtained, among few in the world, Marketing Authorization in the US for a New Drug Application Clorotekal (spinal Chloroprocaine). This is an outstanding achievement. In fact, we are one of the few small medium-sized companies in the world which actually managed to register an original "innovative" product in the United States.
Clorotekal New Drug Application (NDA) is based on a complete dossier, ranging from cell and animal toxicity, to clinical research on human beings, obviously going through pharmaceutical development. Clorotekal is mainly conceived for the fast track spinal anesthesia in day surgery cases, enhancing the recovery after surgery.
Moreover, one radical innovation in the field of pain relief after surgery is under final stages of development. The potential of this innovation could be disruptive all over the world and could enhance the way pain is managed in hospital and at home after surgery.
Augusto Mitidieri is the CEO. He is Italian and Swiss citizen, graduated in Management Engineering from Politecnico di Milano; he also obtained a CAS (Certificate of Advanced Studies) in Economics and Health Policy at the University of Lausanne.
His activity in the pharmaceutical field began as Project Manager for the Engineering Division of Bioren SA, (Bigmar Group) in Couvet (NE).
He went on to become Production & Logistics Manager of Bigmar Pharmaceuticals SA in Barbengo (TI). In 2000 Augusto joined Sintetica SA, Mendrisio (TI) as Production & Engineering Manager. In Sintetica, he also worked as Quality Assurance Manager, before becoming General Manager of the Company in 2004.
Since 2011 Augusto has held the position of Corporate CEO of the Sintetica Group. Under his guidance, Sintetica SA, the oldest pharmaceutical company in Ticino, has undergone a period of extraordinary growth, entered international markets with its high quality products in the field of local anesthesia and pain therapy.
Able to implement a real strategic vision which places the individual at the very centre of corporate decisions, Augusto Mitidieri, together with the whole of Sintetica SA, has gained important international awards and recognition.
“Our people are the biggest asset. That’s why we believe in the great place to work culture.”
“To achieve this leadership by innovation in the context of global growth, we consider strategic partnering and business development the key factors.”
IBM Tops 2020 U.S. Patent List; IBM India 2nd Highest Contributor
SAP Invests €55M to Accelerate Its Cloud Strategy in India
LG Now Has a Controlling Stake In Alphonso
B2B E-Commerce Startup Udaan Raises $280 Million
Digital Healthcare Tech Company DXY Raises $500M
© 2021 CIO Bulletin. All rights reserved.